At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 312 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
ustekinumab 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha Agent(s)
In Brief
A Phase 3 clinical trial evaluating placebo, ustekinumab 45 mg, and 1 other intervention for Arthritis, Psoriatic. Completed, enrolled 312 participants across 80 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy (improvement of signs and symptoms) and safety of ustekinumab in patients with psoriatic arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Psoriatic
CountriesAustria, Canada, France, Germany, Hungary, Poland, Russia, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2010
Enrollment StartMar 2010
Primary CompletionMar 2012
Study CompletionNov 2012
TodayJul 2026
First PostedMar 1, 2010
Enrollment StartMar 1, 2010
Primary CompletionMar 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.3 years ago
Interventions
placebodrug
SC injections
ustekinumab 45 mgdrug
SC injections
ustekinumab 90 mgdrug
SC injections